top of page
![](https://static.wixstatic.com/media/e99b4e_2c9a153bef0445d3bfb520bac8ad96ed.png/v1/fill/w_96,h_54,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/e99b4e_2c9a153bef0445d3bfb520bac8ad96ed.png)
![](https://static.wixstatic.com/media/8e982b_1dd0cf009168427c813de1ea4c6555e5.jpg/v1/fill/w_322,h_188,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/8e982b_1dd0cf009168427c813de1ea4c6555e5.jpg)
![](https://static.wixstatic.com/media/8e982b_4af64af7da714298bb3aabc5e61aa0b5.jpg/v1/fill/w_118,h_118,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/8e982b_4af64af7da714298bb3aabc5e61aa0b5.jpg)
![](https://static.wixstatic.com/media/8e982b_9053277c007a4fbda2b6b64e51a58e59.jpg/v1/fill/w_129,h_142,al_c,lg_1,q_80,enc_auto/8e982b_9053277c007a4fbda2b6b64e51a58e59.jpg)
Healthcare Leadership
Superbugs
Antibiotic Resistance
Brad Spellberg, MD
![](https://static.wixstatic.com/media/8e982b_c1db16b620b5444893885bb551fbc333.jpg/v1/fill/w_334,h_222,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/8e982b_c1db16b620b5444893885bb551fbc333.jpg)
![](https://static.wixstatic.com/media/8e982b_e6b64bee8aea4a248f22ae39d923b45d.jpg/v1/fill/w_280,h_209,al_c,lg_1,q_80,enc_auto/8e982b_e6b64bee8aea4a248f22ae39d923b45d.jpg)
![](https://static.wixstatic.com/media/8e982b_7db7a7fc33f04621941e50e57670a44c.jpg/v1/fill/w_118,h_118,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/8e982b_7db7a7fc33f04621941e50e57670a44c.jpg)
Scientist
Immunotherapy Research
Author
Healthcare Policy Expert
![Lab with Bill Nye.jpg](https://static.wixstatic.com/media/8e982b_3e447bade2c34d90991e03991f6f41cc~mv2_d_3264_2448_s_4_2.jpg/v1/fill/w_939,h_460,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Lab%20with%20Bill%20Nye.jpg)
Spellberg Lab Homepage
We work on the immunology, vaccinology, and host defense against highly resistant infections, including those caused by Acinetobacter, carbapenem-resistant Enterobacteriaceae, and S. aureus. We have an active discovery and development program for monoclonal antibodies targeting A. baumannii. We have a very exciting translational program using a patented combinationof vaccine adjuvants which protects against infection caused by many highly resistant nosocomial pathogens, and is promising as a novel means to prevent hospital acquired infections. The over-arching theme of our lab work is to understand how pathogens interface with host response to cause disease, with an intent to develop immune-modulatory therapeutic interventions to improve morbidity and mortality of these infections.
bottom of page